Alnylam initiates ILLUMINATE-B phase 3 pediatric study of Lumasiran to treat primary hyperoxaluria type 1

Image: Alnylam has initiated ILLUMINATE-B phase 3 pediatric study of Lumasiran to treat primary hyperoxaluria type 1. Photo: courtesy of dream designs / FreeDigitalPhotos.net.